Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,114JPY
2:31am BST
Price Change (% chg)

¥-5 (-0.45%)
Prev Close
¥1,119
Open
¥1,115
Day's High
¥1,119
Day's Low
¥1,111
Volume
1,017,300
Avg. Vol
9,423,418
52-wk High
¥1,340
52-wk Low
¥935

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.60
Market Cap (Mil.): ¥2,529,299.00
Shares Outstanding (Mil.): 2,284.82
Dividend: 14.00
Yield (%): 2.35

Financials

  4503.T Industry Sector
P/E (TTM): 34.37 33.12 33.26
EPS (TTM): 32.21 -- --
ROI: 6.79 19.69 18.95
ROE: 7.21 20.39 19.72
Search Stocks

Aveo, Astellas end pact to develop cancer drug tivozanib

- Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.

14 Feb 2014

UPDATE 1-Aveo, Astellas end pact to develop cancer drug tivozanib

Feb 14 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.

14 Feb 2014

Aveo, Astellas end pact to develop cancer drug Tivozanib

Feb 14 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug and said they would discontinue a mid-stage study testing its use in colon cancer.

14 Feb 2014

FDA warns of heart risks with Astellas stress test chemicals

- The U.S. Food and Drug Administration warned physicians on Wednesday that two chemicals used to conduct cardiovascular stress tests can cause heart attacks and death, and it suggested resuscitation equipment and trained staff be available when the tests are conducted.

20 Nov 2013

BRIEF-FDA warns of heart risks with Astellas' Lexiscan and Adenoscan

Nov 20 - US FDA: * FDA warns of rare but serious risk of heart attack and death with Astellas

20 Nov 2013

Astellas to buy back up to $306 mln worth of own shares

TOKYO, Nov 1 - Japan's Astellas Pharma Inc said on Friday it would buy back up to 5.3 million shares, or 30 billion yen ($306 million) worth of its own stock between Nov. 5 and Dec. 16.

01 Nov 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00
Provider: GlobalData
£81.00
Provider: MarketLine (a Datamonitor Company)
£114.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks